Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Inclusion Criteria

• •The patients signed the written informed consent
• •The patients present with non-metastatic unilateral invasive ER-negative (IHC\<10%), PR-negative(IHC\<10%), HER2-negative breast cancer with a primary breast tumor \> 2cm by imaging or an axillary lymph node \> 2cm by imaging.
• •18 years old\< age \< 70 years old.
• •The patients have no history of hormone therapy, chemotherapy, breast cancer surgery and radiotherapy.
• •The patients have normal cardiac functions by echocardiography.
• •The patients' ECOG scores are ≤2.
• •The patients can swallow pills.
• •The results of patients' blood tests are as follows:
• •* Hb≥90g/L;
• •* WBC≥4E+9/L;
• •* Plt≥100E+9/L;
• •* Neutrophils≥1.5E+9/L;
• •* ALT and AST ≤ triple of normal upper limit;
• •* TBIL ≤ 1.5 times of normal upper limit;
• •* Creatinine ≤ 1.5 times of normal upper limit.